CA
NZ
UK
AU
IND
US
● Adjusted diluted EPS rose 28.8% to $2.37 from $1.84.
● Adjusted operating profit rose 9.7% to £1,364 million, a 24.3% margin.
● The medical expense ratio climbed to 95.3% from 80.0%.
● Net income was $28.1 million, or $0.34 per diluted share.
● Polaryx appointed Will Charlton, M.D., as Chief Medical Officer on September 1.
● The net loss narrowed about 58% to roughly $2.8 million.
Biomea Fusion (NASDAQ:BMEA) fell about 18% in premarket trading on Wednesday, October 14, 2026, according to a live table of decliners. The same table showed steeper drops in several tiny companies, and no press release or filing explaining the move was identified for Biomea …
Investors moved out of technology and into health care on October 14, 2026. A hotter inflation report lifted Treasury yields, which hurt growth stocks, while drug makers and insurers are seen as steadier earners. The S&P 500 health care sector rose 2.44% and consumer …
Arrowhead Pharmaceuticals said on September 29, 2026 that it would host a webinar on Wednesday, October 14, 2026 at 11:30 a.m. PDT to present interim clinical data from a Phase 1/2a study of ARO-MAPT. Speakers included Dr. Adam Boxer of the University of California, …
● The latest earnings report showed a loss of $0.64 per share.
Please wait processing your request...